Clover Biopharmaceuticals closes $43 million Series B investment round
Category: #health  By Mateen Dalal  Date: 2019-11-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Clover Biopharmaceuticals closes $43 million Series B investment round

Clover Biopharmaceuticals, a renowned research-based, clinical-stage biotechnology firm, reportedly announced that it has closed a $43 million Series B investment round.

The investment round was led by Lapam Capital and Delos Capital, with Sichuan Health Care Industry Fund, Betta Capital, Jinlong Group and Beijing Zhongguancun VC also participating in the round.

Concurrent with the investment, Partner at Lapam Capital, Mr. Guangyu Xu, and Principal at Delos Capital, Mr. Tim Xiao, CFA, FRM, would be joining the board of directors at Clover. BFC Group worked as the exclusive financial advisor for Clover was fulfilled in the financing round.

The newly raised capital would be redirected towards the clinical development of the company’s biological candidates. The capital would also go towards the operations of the company’s commercial-scale cGMP biomanufacturing plant as well as the scaling up of its preclinical research and development pipeline using its proprietary and innovative Trimer-Tag technology platform.

President, Co-founder and Chairman of Clover, Dr. Peng Liang, stated that as a science-driven, research-based biotechnology firm, Clover’s mission always has been to deliver its innovative biologic therapies and treatments to the world.

Dr. Peng further added that the company looks forward to using the new proceeds to expedite its drug development programs and get a step closer to its goal of becoming a truly-innovative and first biologics R&D powerhouse based in China.

Board Director and Chief Strategy Officer at Clover, Joshua Liang stated that the company is thrilled to complete this investment round as it would allow the company to advance its leading biologic candidates to late-stage development, grow its internal R&D capabilities while continuing to build a top-of-the-class team.

Lapam Capital Partner, Guangyu Xu stated that Lapam Capital is impressed with Clover’s biologics development capabilities, technology platforms and scientific team. Lapam looks forward to supporting Clover in bringing their impactful as well as innovative medicines to the market efficiently and quickly to benefit patients.

The new capital brings the company’s total raised capital since 2016 to more than $100 million.
 

Source credit: http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=37

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Health insurer Alan acquires Jour to enter the mental health market
Health insurer Alan acquires Jour to enter the mental health market
By Mateen Dalal

Alan, a health insurance startup based in France, has acquired American digital behavioral health firm, Jour for $20 million. The acquisition has assisted the French health insurer to launch its new digital health service, Alan Mind, helping it ...

WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
By Mateen Dalal

South Korean consumer equipment firm, WAVE Electronics has recently formed an alliance with home automation company, Savant Systems, Inc. to provide CYNC™ smart home solutions to its contractors, custom installation professionals, and builders ...

WardWizard Innovations & Mobility to invest $20Mn in EV business
WardWizard Innovations & Mobility to invest $20Mn in EV business
By Mateen Dalal

Indian electric vehicle manufacturer, WardWizard Innovations and Mobility have expressed plans to spend INR 150 crore (USD 20 million) in the coming six months in its EV business, as it seeks to ramp up technology and infrastructure, among other thin...